Coliprotec F4


porcine post-weaning diarrhoea vaccine (live)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 29/01/2020

Authorisation details

Product details
Coliprotec F4
Agency product number
Active substance
live non-pathogenic Escherichia coli O8:K87
International non-proprietary name (INN) or common name
porcine post-weaning diarrhoea vaccine (live)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Prevtec Microbia GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Geyerspergerstrasse 27
80689 München

Product information

15/01/2020 Coliprotec F4 - EMEA/V/C/003797 - R/0005


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for suidae

  • Live bacterial vaccines
  • Pig

Therapeutic indication

For active immunisation of pigs against enterotoxigenic F4-positive Escherichia coli in order to:

  • reduce the incidence of moderate to severe post-weaning Escherichia coli diarrhoea (PWD) in pigs;
  • reduce the colonisation of the ileum and faecal shedding of enterotoxigenic F4-positive Escherichia coli from infected pigs.

Assessment history

How useful was this page?

Add your rating